Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy Kevin D. Mullen, Arun J. Sanyal, Nathan M. Bass, Fred F. Poordad, Muhammad Y. Sheikh, R. Todd Frederick, Enoch Bortey, William P. Forbes Clinical Gastroenterology and Hepatology Volume 12, Issue 8, Pages 1390-1397.e2 (August 2014) DOI: 10.1016/j.cgh.2013.12.021 Copyright © 2014 AGA Institute Terms and Conditions
Figure 1 Rates of HE-related and all-cause hospitalizations for the all-rifaximin and new-rifaximin populations in the OLM compared with patients receiving historical placebo or rifaximin in the 6-month RCT. *P < .0001 vs placebo. Inferential statistics were not conducted for the all-rifaximin and new-rifaximin populations. Clinical Gastroenterology and Hepatology 2014 12, 1390-1397.e2DOI: (10.1016/j.cgh.2013.12.021) Copyright © 2014 AGA Institute Terms and Conditions
Supplementary Figure 1 CONSORT flow diagram. aThe integrated safety population (all-rifaximin population, N = 392) included the new-rifaximin population plus all patients who received rifaximin during the RCT regardless of enrollment into the OLM (gray shaded boxes). CONSORT, Consolidated Standards of Reporting Trials. Clinical Gastroenterology and Hepatology 2014 12, 1390-1397.e2DOI: (10.1016/j.cgh.2013.12.021) Copyright © 2014 AGA Institute Terms and Conditions
Supplementary Figure 2 Antibiotic use time in the all-rifaximin population. Clinical Gastroenterology and Hepatology 2014 12, 1390-1397.e2DOI: (10.1016/j.cgh.2013.12.021) Copyright © 2014 AGA Institute Terms and Conditions